SA521422304B1 - مركبات تشارك في الارتباط التعاوني واستخداماتها - Google Patents
مركبات تشارك في الارتباط التعاوني واستخداماتهاInfo
- Publication number
- SA521422304B1 SA521422304B1 SA521422304A SA521422304A SA521422304B1 SA 521422304 B1 SA521422304 B1 SA 521422304B1 SA 521422304 A SA521422304 A SA 521422304A SA 521422304 A SA521422304 A SA 521422304A SA 521422304 B1 SA521422304 B1 SA 521422304B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- compounds
- participate
- cooperative binding
- ras
- cancers
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000009146 cooperative binding Effects 0.000 title 1
- 102000007474 Multiprotein Complexes Human genes 0.000 abstract 1
- 108010085220 Multiprotein Complexes Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000031018 biological processes and functions Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000002678 macrocyclic compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Abstract
يتعلق الاختراع الحالي بالكشف عن مركبات كبيرة الحلقة، بمفردها وفي توليفة مع عوامل علاجية أخرى، وكذلك بتركيبات صيدلية ومعقدات بروتين protein complexes منها، قادرة على تعديل عمليات بيولوجية biological processes تتضمن تثبيط متجانس الجين الورمي الفيروسي لساركوما الفئران Rat sarcoma viral oncogene homolog (RAS) وتثبيط ارتباط متجانس الجين الورمي الفيروسي لساركوما الفئران بالساركوما الليفية التصاعدية بشكل سريع Rapidly Accelerated Fibrosarcoma (RAF)، واستخدامها في علاج السرطانات cancers. [الشكل 1].
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783816P | 2018-12-21 | 2018-12-21 | |
| US201962894493P | 2019-08-30 | 2019-08-30 | |
| US201962930489P | 2019-11-04 | 2019-11-04 | |
| PCT/US2019/068100 WO2020132597A1 (en) | 2018-12-21 | 2019-12-20 | Compounds that participate in cooperative binding and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA521422304B1 true SA521422304B1 (ar) | 2023-12-21 |
Family
ID=71099011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA521422304A SA521422304B1 (ar) | 2018-12-21 | 2021-06-17 | مركبات تشارك في الارتباط التعاوني واستخداماتها |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20200197391A1 (ar) |
| EP (1) | EP3897644A4 (ar) |
| JP (1) | JP2022520154A (ar) |
| KR (1) | KR20210116479A (ar) |
| CN (1) | CN113498342A (ar) |
| AU (1) | AU2019401466A1 (ar) |
| BR (1) | BR112021012057A2 (ar) |
| CA (1) | CA3123869A1 (ar) |
| IL (1) | IL284210A (ar) |
| MX (1) | MX2021007468A (ar) |
| SA (1) | SA521422304B1 (ar) |
| SG (1) | SG11202106605VA (ar) |
| TW (1) | TW202039509A (ar) |
| WO (1) | WO2020132597A1 (ar) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL264186B1 (en) | 2016-07-12 | 2024-04-01 | Revolution Medicines Inc | 2,5-dimutomers of 3-methylpyrazines and 2,5,6-dimutomers of 3-methylpyrazines as allosteric SHP2 inhibitors |
| IL296456A (en) | 2017-01-23 | 2022-11-01 | Revolution Medicines Inc | Bicyclics as allosteric shp2 inhibitors |
| CN110431134A (zh) | 2017-01-23 | 2019-11-08 | 锐新医药公司 | 作为变构shp2抑制剂的吡啶化合物 |
| BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| CN115873020A (zh) * | 2019-11-04 | 2023-03-31 | 锐新医药公司 | Ras抑制剂 |
| BR112022008565A2 (pt) * | 2019-11-04 | 2022-08-09 | Revolution Medicines Inc | Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras |
| TW202132314A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| US20210322405A1 (en) * | 2020-04-15 | 2021-10-21 | Washington University | Compositions and methods for treating cancer |
| JP2023530351A (ja) | 2020-06-18 | 2023-07-14 | レヴォリューション・メディスンズ，インコーポレイテッド | Ｒａｓ阻害剤への獲得耐性を遅延させる、防止する、及び、治療する方法 |
| IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
| AU2021345111A1 (en) | 2020-09-15 | 2023-04-06 | Revolution Medicines, Inc. | Indole derivatives as Ras inhibitors in the treatment of cancer |
| MX2023007162A (es) * | 2020-12-17 | 2023-06-29 | Blossomhill Therapeutics Inc | Macrociclos y sus usos. |
| MX2023013084A (es) | 2021-05-05 | 2023-11-17 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer. |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| CA3217393A1 (en) | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
| WO2022251292A1 (en) | 2021-05-25 | 2022-12-01 | Revolution Medicines, Inc. | Methods for inhibiting ras |
| US20220395507A1 (en) * | 2021-05-27 | 2022-12-15 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2023015559A1 (en) * | 2021-08-13 | 2023-02-16 | Nutshell Biotech (Shanghai) Co., Ltd. | Macrocycle compounds as inhibitors of ras |
| AR126854A1 (es) | 2021-08-27 | 2023-11-22 | Hoffmann La Roche | Compuestos macrocíclicos para el tratamiento de cáncer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| TW202400607A (zh) * | 2022-04-25 | 2024-01-01 | 美商翰森生物有限責任公司 | 環狀化合物、製備方法及其醫藥用途 |
| WO2023232776A1 (en) | 2022-06-01 | 2023-12-07 | F. Hoffmann-La Roche Ag | Haloindole macrocyclic compounds for the treatment of cancer |
| WO2023240263A1 (en) * | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN117903169A (zh) * | 2022-09-19 | 2024-04-19 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
| WO2024067857A1 (zh) * | 2022-09-29 | 2024-04-04 | 南京明德新药研发有限公司 | 大环衍生物及其应用 |
| CN116284045A (zh) * | 2023-05-18 | 2023-06-23 | 西南交通大学 | 一种手性吲哚单元取代的四氢异喹啉化合物及其合成方法 |
| CN116570599B (zh) * | 2023-07-04 | 2023-10-20 | 四川大学华西医院 | Vs6766联合ly3009120的应用及药物组合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601852B2 (en) * | 2006-05-11 | 2009-10-13 | Kosan Biosciences Incorporated | Macrocyclic kinase inhibitors |
| EP2710018B8 (en) * | 2011-05-19 | 2022-02-23 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Macrocyclic compounds as protein kinase inhibitors |
| AR091279A1 (es) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
-
2019
- 2019-12-20 TW TW108146857A patent/TW202039509A/zh unknown
- 2019-12-20 CA CA3123869A patent/CA3123869A1/en active Pending
- 2019-12-20 WO PCT/US2019/068100 patent/WO2020132597A1/en active Application Filing
- 2019-12-20 MX MX2021007468A patent/MX2021007468A/es unknown
- 2019-12-20 AU AU2019401466A patent/AU2019401466A1/en active Pending
- 2019-12-20 EP EP19901393.9A patent/EP3897644A4/en active Pending
- 2019-12-20 CN CN201980092760.0A patent/CN113498342A/zh active Pending
- 2019-12-20 KR KR1020217022312A patent/KR20210116479A/ko unknown
- 2019-12-20 BR BR112021012057-2A patent/BR112021012057A2/pt unknown
- 2019-12-20 US US16/723,438 patent/US20200197391A1/en not_active Abandoned
- 2019-12-20 SG SG11202106605VA patent/SG11202106605VA/en unknown
- 2019-12-20 JP JP2021535755A patent/JP2022520154A/ja active Pending
-
2021
- 2021-06-17 SA SA521422304A patent/SA521422304B1/ar unknown
- 2021-06-20 IL IL284210A patent/IL284210A/en unknown
-
2023
- 2023-03-16 US US18/184,766 patent/US20240139185A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202106605VA (en) | 2021-07-29 |
| CN113498342A (zh) | 2021-10-12 |
| US20240139185A1 (en) | 2024-05-02 |
| CA3123869A1 (en) | 2020-06-25 |
| BR112021012057A2 (pt) | 2021-10-19 |
| WO2020132597A8 (en) | 2020-07-16 |
| US20200197391A1 (en) | 2020-06-25 |
| TW202039509A (zh) | 2020-11-01 |
| EP3897644A4 (en) | 2022-09-07 |
| IL284210A (en) | 2021-08-31 |
| JP2022520154A (ja) | 2022-03-29 |
| EP3897644A1 (en) | 2021-10-27 |
| MX2021007468A (es) | 2021-08-05 |
| KR20210116479A (ko) | 2021-09-27 |
| WO2020132597A1 (en) | 2020-06-25 |
| AU2019401466A1 (en) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521422304B1 (ar) | مركبات تشارك في الارتباط التعاوني واستخداماتها | |
| CR20220240A (es) | Inhibidores de ras | |
| MX2022005360A (es) | Inhibidores de ras. | |
| MX2022005359A (es) | Inhibidores de ras. | |
| MX2020001513A (es) | Agentes de union a clec9a y su uso. | |
| CR20230165A (es) | Derivados indólicos como inhibidores de ras en el tratamiento del cáncer | |
| MX2020006128A (es) | Inhibidores de la proteina de activacion de fibroblastos. | |
| MX2019001517A (es) | Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer. | |
| WO2018049152A8 (en) | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| EP4276114A3 (en) | Cd20 binding single domain antibodies | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
| MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
| AU2018278311A1 (en) | IRE1 small molecule inhibitors | |
| CR20230570A (es) | Inhibidores de ras | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| MX2021011723A (es) | Ligandos de pseudocinasa tyk2. | |
| MX2020008208A (es) | Agentes de unión a fibroblastos y uso de estos. | |
| MX2021009555A (es) | Ligandos de pseudocinasa tyk2. | |
| MX2018015172A (es) | Metodos para tratar cancer pancreatico. | |
| MX2018008645A (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| MX2022005563A (es) | Ligandos de la pseudoquinasa tyk2. |